makena fda, fda makena, makena fda, makena approval, makena fda approval
makena fda, fda makena, makena fda, makena approval, makena fda approval
makena fda, fda makena, makena fda, makena approval, makena fda approval
    makena fda, fda makena, makena fda, makena approval, makena fda approval  
makena fda, fda makena, makena fda, makena approval, makena fda approval



In the news


K-V Pharmaceutical Company Appoints Healthcare Veteran, Gregg Raybuck, to Lead New Maternal Health Division
February 21, 2014

K-V Pharmaceutical Company Clinical Study on Reducing the Risk of Recurrent Preterm Birth Becomes Largest of Its Kind
January 21, 2014

K-V Pharmaceutical Company ("KV") today announced the appointment of Janet Vergis to its Board of Directors.
November 05, 2013

K-V Pharmaceutical Company ("KV") today announced the appointment of two new members to its Board of Directors: Gregory Norden and James M. Goldfarb.
October 11, 2013

K-V Pharmaceutical Company ("KV") today announced the appointment of Joseph M. Mahady as Chairman of its Board of Directors.
October 03, 2013


Product Recall

Ask the Healthcare
Professional





A specialty pharmaceutical company committed to women's healthcare.

Headquartered in St. Louis, Missouri, KV Pharmaceutical is a specialty pharmaceutical company with a focus on women’s healthcare. Through our operations subsidiary, Ther-Rx Corporation, we develop, distribute, and support a portfolio of pharmaceutical products that healthcare providers can prescribe with confidence, and pharmacists can dispense with trust. Ther-Rx’s employees are passionately committed to advancing the health of women across all the stages of her life. Click here to learn more about us.

Ther-Rx Corporation Announces the Availability of Clindesse® (Clindamycin Phosphate) Vaginal Cream, 2% for Prescribing

Single dose prescription treatment for bacterial vaginosis now available for prescribing

St. Louis, August 5, 2013 – Ther-Rx Corporation, a women's health-focused pharmaceutical company and subsidiary of K-V Pharmaceutical Company (OTCQB Marketplace: KVPHQ/KVPBQ) announced today that Clindesse® (clindamycin phosphate) Vaginal Cream, 2% indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women, is now available for prescribing. Wholesalers have ordered and received product and are distributing to retail pharmacies.

“We are pleased to be able to once again offer Clindesse,” said Greg Divis, CEO of Ther-Rx and K-V. “Together with Gynazole-1®’s reintroduction in January, the availability of Clindesse represents a key positive milestone for the Company as the two products comprising our anti-infectives franchise are both available for prescribing.”

Bacterial vaginosis (BV) is a complex polymicrobial infection that results from an overgrowth of a number of different bacterial species and is the most common vaginal infection in women of childbearing age. Clindesse has been used to treat 2.2 million women and is the first and only single-dose therapy approved for the treatment of BV in non-pregnant women.

Click here to view the full Company Statement.















makena fda, fda makena, makena fda, makena approval, makena fda approval
Home | Contact Us | Site Directory | Legal/Privacy | Compliance Program ©2014 KV Pharmaceutical Company. All Rights Reserved.
<